

1 **Risk scores for predicting HIV incidence among the general population in sub-**  
2 **Saharan Africa: a systematic review and meta-analysis**

3 Katherine M. Jia<sup>1</sup>, Hallie Eilerts<sup>2</sup>, Olanrewaju Edun<sup>1</sup>, Kevin Lam<sup>1</sup>, Adam Howes<sup>3</sup>, Matthew L.  
4 Thomas<sup>4</sup>, Jeffrey W. Eaton<sup>1§</sup>

5

6 <sup>1</sup> MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial  
7 College London, London, United Kingdom

8 <sup>2</sup> Department of Population Health, The London School of Hygiene and Tropical Medicine,  
9 London, United Kingdom

10 <sup>3</sup> Department of Mathematics, Imperial College London, London, United Kingdom

11 <sup>4</sup> Joint Centre for Excellence in Environmental Intelligence, University of Exeter & Met Office,  
12 Exeter, United Kingdom

13

14 <sup>§</sup>Corresponding author: Jeffrey W. Eaton

15

16 MRC Centre for Global Infectious Disease Analysis, School of Public Health  
17 Imperial College London  
18 St. Mary's Hospital Campus  
19 Norfolk Place  
20 London W2 1PG  
21 United Kingdom  
22 +44 20 7594 3007  
23 [jeffrey.eaton@imperial.ac.uk](mailto:jeffrey.eaton@imperial.ac.uk)

24

25 E-mail addresses of authors:

26 KMJ: [katherine.jia19@imperial.ac.uk](mailto:katherine.jia19@imperial.ac.uk)

27 HE: [hallie.eilerts@lshtm.ac.uk](mailto:hallie.eilerts@lshtm.ac.uk)

28 OE: [o.edun19@imperial.ac.uk](mailto:o.edun19@imperial.ac.uk)

29 KL: [kevin.lam@imperial.ac.uk](mailto:kevin.lam@imperial.ac.uk)

30 AH: [a.howes19@imperial.ac.uk](mailto:a.howes19@imperial.ac.uk)

31 MLT: [M.L.Thomas@exeter.ac.uk](mailto:M.L.Thomas@exeter.ac.uk)

32 JWE: [jeffrey.eaton@imperial.ac.uk](mailto:jeffrey.eaton@imperial.ac.uk)

33

34 Keywords: risk scores, HIV incidence, sub-Saharan Africa, adolescent girls and young  
35 women, risk factors for HIV incidence

36

37 Word count: Abstract: 346/350 words; Main text: 4424/5000 words

## 38 **Abstract**

39 **Introduction:** Several HIV 'risk scores' have been developed to identify individuals for  
40 prioritised HIV prevention in sub-Saharan Africa. We systematically reviewed HIV risk scores  
41 to: (i) identify factors that consistently predicted incident HIV infection, (ii) review inclusion of  
42 community-level HIV risk in predictive models, and (iii) examine predictive performance.

43 **Methods:** We systematically searched nine databases for studies developing and/or  
44 validating HIV risk scores among the general population in sub-Saharan Africa from  
45 database inception until February 15, 2021. Studies not prospectively observing  
46 seroconversion or recruiting only key populations were excluded. Record screening, data  
47 extraction, and critical appraisal were conducted in duplicate. We used random-effect meta-  
48 analysis to summarise hazard ratios and the area under the receiver-operating characteristic  
49 curve (AUC-ROC).

50 **Results:** From 1563 initial search records, we identified 14 risk scores in 13 studies. Seven  
51 studies were among sexually active women using contraception enrolled in randomised-  
52 controlled trials, three among adolescent girls and young women (AGYW), and three among  
53 cohorts enrolling both men and women. Consistently identified HIV prognostic factors among  
54 women were younger age (pooled adjusted hazard ratio: 1.62 [95% Confidence Interval: 1.17,  
55 2.23], compared to above-25), single/not cohabiting with primary partners (2.33 [1.73, 3.13])  
56 and having sexually transmitted infections (STIs) at baseline (HSV-2: 1.67 [1.34, 2.09];  
57 curable STIs: 1.45 [1.17; 1.79]). Among AGYW only STIs were consistently associated with  
58 higher incidence, but studies were limited (n=3). Community-level HIV prevalence or  
59 unsuppressed viral load strongly predicted incidence but were only considered in three of 11  
60 multi-site studies. The AUC-ROC ranged from 0.56 to 0.79 on the model development sets.  
61 Only the VOICE score was externally validated by multiple studies, with pooled AUC-ROC  
62 0.626 [0.588, 0.663] ( $R^2$ : 64.02%).

63 **Conclusions:** Younger age, non-cohabiting, and recent STIs were consistently identified as  
64 predicting future HIV infection. Both community HIV burden and individual factors should be  
65 considered to quantify HIV risk. However, HIV risk scores had only low-to-moderate  
66 discriminatory ability and uncertain generalizability outside of the study populations. Further  
67 evidence on the relative value of specific factors and data outside high-risk populations will  
68 help inform optimal implementation of risk scoring algorithms in HIV programmes.

69 **PROSPERO Number:** CRD42021236367

## 70 **Introduction**

71 Efficiently identifying populations and individuals at highest risk of HIV infection and linking  
72 them to HIV prevention is essential for continued progress towards ending HIV as a public  
73 health threat [1]. This is especially the case for expensive and intensive interventions, such  
74 as pre-exposure prophylaxis (PrEP) [2, 3], and in sub-Saharan where 59% of 1.7 million  
75 global new infections in 2019 occurred and a large proportion of HIV infections occur among  
76 persons who do not identify as key populations among whom HIV is concentrated in other  
77 global regions [4].

78 Efficiently identifying those at high risk of acquiring HIV from the large population is essential  
79 for efficiently and effectively delivering HIV prevention. Several HIV incidence ‘risk scores’  
80 have been proposed as prognostic tools for this purpose [5, 6]. HIV risk scores combine data  
81 on multiple prognostic factors into a single score, which is often compared against a  
82 threshold to classify individuals among whom specific HIV prevention services are offered or  
83 promoted. An optimal threshold maximises the share of incident infections among the higher  
84 risk group while minimizing the total proportion classified as such, but there is typically a  
85 trade-off between these. Risk scores are empirically derived using data from large-scale,  
86 longitudinal studies like HIV randomised controlled trials (RCTs) and cohort studies that  
87 collect comprehensive HIV prognostic factors spanning the behavioural, sociodemographic,  
88 partnership domains among HIV negative adults and prospectively measure HIV incidence,  
89 usually within 1 year or less after the baseline risk assessment. Generalisability is validated  
90 by applying the risk score to independently collected data and studying how well the score  
91 discriminates those who subsequently acquire HIV.

92 Recently, national HIV programmes have focused on prioritising interventions to geographic  
93 areas with high HIV burden [1]. This strategy is epidemiologically justified for two reasons:  
94 high HIV burden indicates previous high HIV risk, and, secondly, high HIV prevalence or  
95 unsuppressed HIV viraemia implies greater exposure to HIV infection among those currently  
96 at risk [7, 8]. This community-level determinant of exposure does not fit naturally into the

97 individual-level risk framework of risk scoring. However, solely geographic prioritisation of  
98 HIV prevention is inefficient by not considering individual-level variation measured by risk  
99 scores.

100 Mathematical modelling has demonstrated that considering both geographic location and risk  
101 populations in prioritising of HIV prevention improves the efficiency and cost-effectiveness  
102 relative to only one dimension [9]. The new Global AIDS Strategy 2021-2026 embraces this  
103 approach—recommending that HIV prevention is prioritised for various population groups  
104 differentiated according to thresholds for the local HIV incidence [10]. For example, for  
105 adolescent girls and young women (AGYW), the strategy recommends prioritisation of  
106 services to those at high risk based on: (i) the subnational annual incidence greater than 3%,  
107 or (ii) an incidence of 1-3% and self-reported high-risk behaviours or recent sexually  
108 transmitted infection (STI) [10].

109 We conducted a systematic review of HIV risk score tools in sub-Saharan Africa to explore  
110 this from both perspectives. Firstly, to motivate improved modelling of HIV incidence and  
111 prioritising of HIV prevention, we sought to identify prognostic factors from the HIV risk score  
112 literature that stratify population HIV risk, and the ability of these factors to discriminate HIV  
113 incidence within a population. Secondly, we queried the extent to which HIV risk scores  
114 considered community-level HIV prevalence or population viraemia as a predictor in  
115 prognostic models for individual HIV incidence risk. Specifically, we searched literature for  
116 studies that either developed or validated a HIV incidence risk score model among the  
117 general population, and analysed the data to: (i) identify risk factors that have consistently  
118 shown strong effects on HIV incidence across different models and settings, (ii) evaluate  
119 whether community-level HIV prevalence has been considered as a determinant of HIV risk  
120 in risk score development, and (iii) examine the efficiency of risk scores in differentiating  
121 high- and low-risk individuals quantified by the area under the receiver-operating  
122 characteristic curve (AUC-ROC).

## 123 **Methods**

124 **Search strategy.** We searched for studies that developed and/or validated the HIV incidence  
125 risk scores among the general population of sub-Saharan Africa. Specific inclusion criteria  
126 were: (i) development and/or validation of any predictive multivariable model (“risk score”)  
127 with prospectively measured HIV incidence as the main outcome (i.e., documented HIV-  
128 negative status at baseline), (ii) enrolled from the general population and (iii) conducted in  
129 sub-Saharan African countries. Studies were excluded if: (i) HIV seroconversions were not  
130 determined by a HIV negative test result at baseline followed by a positive or negative result  
131 during follow-up, (ii) study populations were key or selected populations only (men who have  
132 sex with men, female sex workers, pregnant women, serodiscordant couples, HIV-exposed  
133 infants, people who inject drugs).

134 Keywords, synonyms, and related terms covered the domains of “sub-Saharan Africa”,  
135 “HIV/AIDS”, and “risk score”. The full electronic search strings for all databases are available  
136 in the Supplementary Material (Appendix I). No restrictions were imposed on the types nor  
137 years of publications; however, only publications written in English were included.

138 **Sources of information.** Nine databases were searched: MEDLINE, Embase, Global Health,  
139 PsycINFO, Maternity & Infant Care Database, CINAHL (EBSCO), Scopus, Cochrane Library,  
140 the Web of Science, on 15<sup>th</sup> February 2021.

141 **Study selection.** Titles and abstracts were independently screened by two reviewers for  
142 eligibility against the inclusion and exclusion criteria. Discrepancies were resolved by either  
143 consensus after discussion or decision of a third reviewer. After abstract screening, study full  
144 texts were reviewed for inclusion by two independent reviewers. Reasons were provided for  
145 any exclusion of studies at this stage. Again, any discrepancies in decisions or reasons were  
146 resolved through discussion or by a third reviewer.

147 **Data extraction and risk of bias assessment.** Data were extracted by two independent  
148 reviewers, with discrepancies resolved through discussion. We referred to the Critical

149 Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies  
150 (CHARMS) Checklist when creating the data extraction form (Appendix II).<sup>[11]</sup> After extraction,  
151 two reviewers assessed the risks of bias for each study independently using the Prediction  
152 Model Risk of Bias (PROBAST) assessment tool checklist,<sup>[12]</sup> under the four domains  
153 ‘Population’, ‘Predictor’, ‘Outcome’ and ‘Analysis.’ A domain where one or more criteria  
154 was/were not fulfilled might be judged as “high risk of bias,” whereas a study with one (or  
155 more) domain(s) at “high risk of bias” would be judged as having an overall “high” risk of bias.

156 **Data synthesis and reporting.** Our aim was to identify significant and measurable  
157 prognostic factors that define high risk groups or individuals for prioritised HIV prevention.  
158 We first summarised the key characteristics, setting, and study population(s) of each  
159 included study, and whether it developed a risk score, externally validated a score, or both. A  
160 development study could conduct internal validation by using re-sampling methods  
161 (bootstrap or cross-validation) to estimate the AUC-ROC, or by splitting the sample into  
162 training and testing sets; external validation where the risk score was applied to a different  
163 study population than which it was originally derived can be performed in the same analysis  
164 or by others in follow-up studies. We then assessed the importance of each predictor by  
165 examining (i) the number of times it was included in the final risk prediction model of a model  
166 development study, (ii) the summary of the adjusted and unadjusted effect size estimates.  
167 Finally, we summarised the area under the receiver operating characteristic curve (AUC-  
168 ROC), proportion identified “high risk” by each score, and the corresponding HIV incidence in  
169 the high-risk group, to assess the risk scores discrimination and compared them across  
170 settings to examine generalisability.

171 Overall summary effect size estimates (and the 95% confidence interval) for predictors were  
172 estimated by a random effects model. Estimates were pooled for both the adjusted and  
173 unadjusted effects because adjusted effects were only available in studies that included the  
174 particular predictors in the multivariable models (due to significant univariate association),  
175 risking biasing summary estimates away from null. Between-study variance were reported

176 with the  $I^2$  statistics to evaluate the heterogeneity. Random effects meta-analysis based on  
177 the inverse variance method with Sidik-Jonkman estimator for between-study variance was  
178 done in R (version 4.0.3) [13] using the packages “meta” and “metafor” [14, 15]. Meta-  
179 analysis for AUC-ROC was performed using methods described by Zhou and colleagues in  
180 Medcalc (version 19.8) [16, 17]. Forests plots and funnel plots were created using the  
181 package “meta” and Medcalc respectively.

182 Protocol of this systematic review is available on PROSPERO (CRD42021236367) [18]. We  
183 referred to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-  
184 Analyses) checklist for presenting the review [19].

185

## 186 **Results**

187 Database searches identified 2029 records; 466 duplicates were removed and 1563 titles  
188 and/or abstracts were screened, of which 25 studies were retained for full-text screening.  
189 One additional conference abstract was available after initial screening, adding to a total of  
190 13 risk score literature (9 peer-reviewed articles, 2 posters, 1 editorial letter, 1 abstract) that  
191 met the inclusion criteria and were included in this review (Figure 1) [5, 6, 20-30]. Critical  
192 appraisal according to the PROBAST checklist concluded that one out of twelve models  
193 developed and two out of nine validated were of low risk of bias (Figure S1, Table S3 & S4).  
194 Inadequate adjustment for over-fitting or model optimism was common among the  
195 development studies (six out of nine). For the validation studies, inadequate sample size  
196 (four out of nine) and missing predictors (five of out nine) were common limitations. Studies  
197 also reported a high proportion of missing cases and/or loss-of-follow-up, but did not often

198 **Study populations.** Studies were conducted in South Africa (n=10), Uganda (n=4), Malawi,  
199 Zimbabwe (n=3), Kenya (n=2), Zambia (n=1), and Tanzania (n=1). Three enrolled multi-  
200 country study populations, and eight were multi-site within one country (Table 1). Incidence  
201 and risk factor data were collected before 2012 for seven studies and after 2012 for six. The  
202 majority (10 of 13) were among women only, of which three were restricted to young women  
203 under age 25 or lower; 3 included women and men aged 15–49 years or 15 years and older.  
204 The majority (10 of 13) were RCTs or quasi-experimental studies that restricted recruitment  
205 and/or eligibility to specific at-risk population groups: (i) sexually active, contraception-  
206 seeking women who attended the family-planning, STIs or research clinics (7 of 10, all RCTs)  
207 [5, 6, 20-24], or (ii) school-attending AGYW (3 of 10) [25-27]. The remaining three were  
208 large-scale cohort studies or community trials that recruited all consenting members within  
209 the communities [28-30]. Geographic locations, study periods, age groups, and settings are  
210 given in Table 1.

211 **Factors included in HIV risk scores.** Nine studies reported on development of 14 HIV risk  
212 scores, involving screening and model selection for predictors of HIV incidence (Table 1).

213 Balzer used a machine learning approach which did not yield effect estimates for individual  
214 risk factors [29], and final regression results were not available for Roberts (abstract only)  
215 [30]. For the remaining studies, Table 2 reports the predictors considered for inclusion and  
216 retained in the final model for each independently developed score. The '*retainment ratio*'  
217 reports the number of times a risk factor was retained in the final score relative to the number  
218 of times it was considered as a '*candidate*' predictor, tabulated separately for risk scores for  
219 women of all ages and for AGYW only study populations.

220 Among four risk scores developed for women of all ages recruited from RCTs who were  
221 sexually active and using contraception, factors retained in all or three of four final models  
222 were: not being married or cohabiting with primary partner (pooled adjusted hazard-ratio  
223 [aHR] 2.33; 95% CI [1.73, 3.13]; Table S5); younger age (pooled aHR: 1.62 [1.17, 2.23]; less  
224 than 25 years old except for Peebles [6] at 27 years), and curable STIs at baseline (pooled  
225 aHR 1.45 [1.17, 1.79]) (Figure 2). Human Simplex Virus – 2 (HSV-2; pooled aHR 1.67 [1.34,  
226 2.09]) and multiple sexual partners (Pooled aHR: 1.62 [1.27, 2.07]) were included in two of  
227 four risk scores. Other demographic, partnership, biological or community factors were either  
228 seldomly considered as candidate predictors or only retained in one or fewer risk scores  
229 (Table 2). Among unselected candidate predictors, educational attainment, employment (or  
230 earning own income) and coital frequency were considered by all four studies but not  
231 retained in any of the final models (Table S1, Supplementary Materials).

232 Three risk scores were developed specifically for sexually active AGYW (aged 13-24, varying  
233 across studies) (Table 2). HSV-2 was the only factor selected in all three (pooled aHR: 1.77  
234 [1.24; 2.54]). Factors selected in two of three models were curable STIs (pooled aHR: 2.14  
235 [1.40; 3.25]), having multiple partners (pooled aHR: 1.76 [1.19; 2.60]) and partner having  
236 other sexual partners (pooled aHR: 2.35 [0.48; 11.53]) (Figure 3). Being not  
237 married/cohabiting was not selected in any final models, unlike the models for all age  
238 women where it was selected by all models.

239 In summary, marital/cohabiting status had been consistently identified and had the largest  
240 effect size estimates in studies among women in general, while for AGYW STIs had showed  
241 greatest consistency and effect sizes. Of the remaining predictors, occupation, self-perceived  
242 HIV risk, partners' occupation, having new partners, engaging in high-risk sex (e.g., under  
243 alcohol use), knowledge of partner's HIV status showed significant associations but were  
244 seldomly assessed [28].

245 ***Inclusion of community HIV prevalence.*** Only three of 11 multi-site studies considered  
246 community-level HIV prevalence as a covariate and all cases where considered it was  
247 selected into one or more of the final models [6, 28, 30]. In Peebles [6], compared to residing  
248 in a community with 10-15% HIV prevalence, those in a community with 16-20% prevalence  
249 had an aHR of 1.64 [1.08, 2.48], 1.71 [0.99, 2.96] for 21-25% prevalence, and 1.81 [1.03,  
250 3.19] for 26-30%. Similarly, in Kagaayi [28], an aHR of 1.03 was associated with each  
251 percentage-point increment in community prevalence for both male [0.99,1.07] and female  
252 [1.01, 1.06]. Roberts [30] also found community HIV prevalence and unsuppressed viral load  
253 to be highly predictive, but aHRs were not available.

254 ***Predictive performance of the risk scores.*** We identified 14 risk scores from nine model  
255 development studies (three models developed by Balzer were considered separately) [29]  
256 (Table 3). When applied to the original data set from which it was developed, the scores had  
257 low-to-moderate AUC-ROC ranging from 0.56 to 0.79. Only the VOICE score has been  
258 externally validated in other settings. In seven validation studies with AUC-ROC estimates,  
259 the accuracy was lower (pooled AUC-ROC: 0.626 [0.588, 0.663];  $F^2$ : 64.02%) than in the  
260 internal validation (AUC-ROC: 0.69 [0.66, 0.72]) (Table 3, Figure 4). In addition to being  
261 among different study populations, it was common for one or two predictors to be missing in  
262 external validation sets (Table 3), which may have also contributed to decreased accuracy.  
263 Regarding validation of other scores, Roberts developed their risk scores in a large-scale  
264 cohort and validated them using data collected in a subsequent time period, also showing

265 moderate discriminatory power (AUC-ROC 0.68 among female and 0.72 among male; Table  
266 3).

267 Several studies compared the discriminative power of combining multivariate risk scores  
268 versus single risk factors. Balkus [5] reported that marital status/cohabitation with primary  
269 partner alone yielded an AUC-ROC of 0.62 versus 0.69 for the full score, followed by age  
270 (0.60) and curable STIs (0.57). In a similar analysis, Peebles<sup>6</sup> found the most important  
271 predictors were age (less than 27), being married/cohabiting and the provinces of residence.  
272 Three studies [5, 6, 24] additionally provided a “modified score” that excluded the laboratory-  
273 diagnosed STIs, which are not routinely available in most settings. Removing laboratory-  
274 diagnosed STIs reduced the AUC-ROC by between one to eight percentage-points (Table 3).  
275 Roberts found that including only age, HIV prevalence, and viraemia as predictors produced  
276 an AUC-ROC of 0.65 for women compared to 0.68 when all risk factors were considered,  
277 and 0.71 for men compared to 0.72 when all risk factors were considered (Table 3).

278 ***Incidence among risk group categories.*** Most studies found that HIV incidence increased  
279 monotonically with the risk scores, except for Giovenco [25] (Table S6). Figure 5 shows the  
280 proportion of participants identified as high risk compared to the percentage of incident cases  
281 contributed by the high-risk group. In six of nine external validation sets of the VOICE score  
282 with such information available (Table S6), women with a VOICE score of 5 or above (having  
283 around 3 to 4 of the 7 risk factors) had incidence above 3%, the WHO-recommended  
284 threshold for PrEP prioritisation. Among studies collecting for all predictors that were  
285 intended by the VOICE score (maximum score: 11), above 60% of women scored 5 or above  
286 [5, 23, 24]. The threshold for which the observed incidence was >3% varied across  
287 populations: in South African samples, Peebles[6] found that incidence was >3% if AGYW  
288 scored 3 out of 11, while among the older sample aged 25-34 years only those scoring 6 out  
289 of 7 had incidence >3% (16.7% of the sample); in KwaZulu-Natal, Wand [21] observed >3%  
290 incidence for 88% of women enrolled in five clinical trials, while in an observational cohort  
291 only 60% (3<sup>rd</sup> quintile and above) of women had incidence >3% [30].

## 292 **Discussion**

293 National HIV programmes in high HIV prevalence settings in sub-Saharan Africa are now  
294 considering whether and how to implement HIV risk scoring tools to support identification and  
295 prioritisation of populations and individuals for HIV prevention, especially oral PrEP and  
296 anticipated future prevention technologies. Our systematic review identified several scoring  
297 algorithms developed or validated for this purpose. Risk score development has especially  
298 focused on sexually active women of reproductive age or adolescent girls and young women.  
299 Only three studies included men and women. Among all sexually active women, younger age,  
300 not being married/cohabiting, and history of STIs (at baseline or lifetime) were consistently  
301 identified as prognostic factors. Among sexually active AGYW, history of STIs remained  
302 consistently selected, but being non-cohabiting was not consistently identified.

303 Risk scoring based on multiple predictors can improve efficiency in identifying individuals at  
304 higher risk of acquiring HIV compared to using individual risk factors [6, 31], but the  
305 improvement was only marginal (<0.1 increase in AUC-ROC) [31]. HIV incidence increased  
306 steadily with risk score in both development and validation studies, but the ability of risk  
307 scores to predict HIV incidence was only moderate. AUC-ROC values ranged from 0.56 to  
308 0.79. AUC-ROC measures the discriminative power of the risk score defined as the  
309 probability that a risk score can successfully predict a HIV incident case from a case-and-  
310 control pair [32]. An AUC-ROC equal to 1 implies the model is able to perfectly discriminate  
311 those who will acquire HIV and those who do not, while 0.5 implies the model has no  
312 discriminative power. Most were lower than the AUC-ROC of scores developed for specific  
313 populations of sero-discordant couples (AUC-ROC: 0.70 [0.64, 0.76] and 0.76 [0.70,0.83] for  
314 two external validation) [33], men-having-sex-with-men in Kenya (0.76 [0.71,0.80]; derivation  
315 set) [34], and pregnant and post-partum women in Kenya (0.84 [0.72, 0.95] for derivation set;  
316 0.73 [0.57,0.90] for internal validation set) [35]. The VOICE score was the only model  
317 externally validated by multiple studies (nine). Predictive performance of VOICE varied  
318 greatly across studies, even among those with all the predictors collected from women in

319 general, which is the original intended population. Among AGYW-only populations, the  
320 discriminative power of the VOICE score is expected to be lower because one of the factors,  
321 younger age, is fulfilled by everyone in the sample. The substantial variation across settings  
322 suggests need for local validation of risk scores before implementation.

323 Only three of eleven multisite studies considered community-level HIV prevalence or  
324 viraemia as a prognostic factor, but all showed it being highly predictive [6, 28, 30]. This  
325 supports recommendations to consider both community-level exposure and individual factors  
326 to assess individual HIV risk and optimal prevention options. In fact, Roberts found that  
327 adding factors beyond community viraemia and age only modestly improved predictive ability,  
328 questioning the added value of potentially burdensome screening for more detailed risk  
329 behaviours [30]. In contrast, in their analysis adjusted for study sites, Balkus identified  
330 cohabitation as the most predictive factor, but additional covariates also substantially  
331 improved predictions [5]. Further data across multiple settings to adjudicate the added value  
332 of more detailed individual risk assessment will help guide HIV programme implementation  
333 strategies.

334 There are several possible reasons risk scores based on well-established risk factors are  
335 only moderately discriminative. First, HIV risk can change rapidly over short time intervals  
336 with life course events. Risk assessed at baseline may only be moderately predictive of an  
337 individual's actual HIV risk six to twelve months later. Second, adults with behaviour  
338 considered 'low risk', such as a single cohabiting sex partner, could still be exposed to high  
339 risk of HIV infection if their partner acquires HIV. While the HIV incidence rate among this  
340 group is relatively low, it may contribute a large proportion of total new infections,  
341 fundamentally limiting the extent to which HIV prevention can be optimised without specific,  
342 timely, and accurate information about risk among sexual partners. Third, factors included in  
343 risk scores are susceptible to reporting or measurement errors to varying degrees. Recent  
344 STI infection, identified through laboratory diagnosis in the clinical trials used for risk score  
345 development, was the most consistently identified predictive factor for HIV infection. However,

346 laboratory testing for STIs is not routinely available in most low- and middle-income countries,  
347 where they were typically diagnosed through syndromic management instead. In our review,  
348 validation studies using self-reported or syndromic identified STIs [23, 24, 26] had similar  
349 accuracy (AUC-ROCs) as those using laboratory tests [6] (Table 3), but elsewhere  
350 syndromic management has consistently had only low to moderate accuracy [36-38].

351 Generalising and applying the risk scores and HIV incidence rate ratios reviewed here across  
352 high HIV burden settings faces several challenges. Data were disproportionately from South  
353 Africa, which has unique HIV epidemiology and low rates of marriage and cohabitation  
354 compared to neighbouring countries. Second, some data used to develop and validate risk  
355 scores were relatively old, with about half of studies completed before 2012 when HIV  
356 incidence was higher and ART coverage lower. Third, most studies were among randomised  
357 clinical trial study populations restricted to sexually active women seeking contraception,  
358 intentionally selected as relatively high-risk for testing novel HIV prevention technologies.  
359 Risk factors identified among this population are likely to generalise to a full adult population,  
360 but estimated AUC-ROC and pooled risk ratios should only be generalised with caution and  
361 appropriate adjustment. Fourth, there were subtle differences in definition and coding of risk  
362 factors across studies. This undermines the appropriateness of our pooled risk ratio  
363 estimates. In many validation studies, some selected risk factors were not available or  
364 defined differently [25, 26, 39].

365 More generally, developing risk scores for HIV incidence is fundamentally challenging,  
366 resulting in moderate to high assessed risk of bias using the PROBAST checklist (Table S3).  
367 As HIV infection is a relatively uncommon event, in most studies the ratio of cases observed  
368 to risk factors considered was far lower than recommended. Many studies were limited in  
369 accounting for over-fitting and model optimism, clarity about handling missing data [12]. Our  
370 review was also constrained by incomplete reporting of multivariate regression results of  
371 initial and final models in some studies. Only a few studies compared the AUC-ROC of the  
372 full models with that of individual predictors, making it difficult to draw conclusions about the

373 necessity of detailed risk assessment compared to a few key characteristics—a key question  
374 for HIV programme implementation. Finally, we only focused on the general population and  
375 did not consider risk scores among key and vulnerable populations with high incidence.  
376 Other epidemiological evidence strongly supports prioritisation and provision of HIV  
377 prevention for these groups where they can be identified.

378 Our review identified three priorities for future studies. First, comparison of the AUC-ROCs of  
379 the full model versus individual predictors or more parsimonious models will help differentiate  
380 key predictors for identifying risk groups and prioritising resources and the relative value of  
381 factors that are more invasive or intensive to collect. Use of machine-learning techniques has  
382 also showed a potential to improving prediction accuracy and can be incorporated into some  
383 prevention interventions [40]. Second, additional risk score development and validation using  
384 recent incidence data from wider geographic settings will increase the generalisability of HIV  
385 risk scores. Finally, although in our review all AUC-ROCs in the external validation studies  
386 fell below 0.7, classified as poor discrimination by some [32], the discrimination of the risk  
387 scores may be higher when applied outside selected RCT populations. This could be  
388 explored through modelling, and further extended to study the infections averted, resources  
389 saved, and cost effectiveness of incorporating multivariable risk scores into risk stratification  
390 and prevention strategy prioritisation. Our findings inform such analyses by providing data on  
391 the incidence rate ratios and proportion of infections among each group compared to the size  
392 of the group.

### 393 **Conclusion**

394 Several risk scores have been developed for identifying individuals at increased risk for HIV  
395 among general populations in sub-Saharan Africa. For women, these have consistently  
396 identified younger age, not being married/cohabiting and STIs as risk factors. However,  
397 taken together, the programmatic benefit of implementing HIV risk scores as screening or  
398 triaging tools may be limited due to only moderate overall discriminatory ability and limited  
399 improvement compared to focusing on geographic areas with high HIV burden and basic

400 demographics such as age group. The marginal benefits must be balanced with additional  
401 administrative burden for providers and consideration for whether screening questions could  
402 be perceived as stigmatizing, invasive, or demotivating for clients. Generalizability of  
403 proposed risk scores is uncertain because tools have been developed among relatively high-  
404 risk study populations and in South Africa and validations have been limited with moderate  
405 risk of bias.

406 **Competing interests**

407 JWE reports grants from Bill and Melinda Gates Foundation and UNAIDS during the conduct  
408 of the study; grants from NIH, UNAIDS, and WHO and personal fees from WHO outside the  
409 submitted work. All other authors declare no competing interests.

410

411 **Authors' contributions**

412 KMJ and JWE conceptualised the review. KMJ did the initial literature search and wrote the  
413 protocol with substantial inputs from JWE. AH, HE, OE, KMJ, KL, and MT screened abstracts  
414 and full texts, extracted the data, and performed critical appraisal. KMJ performed the  
415 analysis and wrote the first draft of the manuscript with substantial inputs from JWE, OE and  
416 AH. KMJ, JWE, AH, HE, OE, KL, and MT contributed to interpretation of the results and  
417 edited the manuscript for intellectual content. All authors read and approved the final version  
418 of the manuscript.

419

420 **Acknowledgments**

421 This research was supported by the Bill & Melinda Gates Foundation (Grant numbers:  
422 OPP1190661, INV-002606, OPP1164897), UNAIDS, and the MRC Centre for Global  
423 Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical  
424 Research Council (MRC) and the UK Foreign, Commonwealth & Development Office  
425 (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2  
426 programme supported by the European Union.

427

428 We thank Natsuko Imai for providing technical guidance and support, Adam Akullian and  
429 Allen Roberts for providing useful comments and unpublished details of their study in this  
430 review.

431

432 **Additional files:**

433 Additional file 1: Risk scores for predicting HIV incidence among general population in sub-  
434 Saharan Africa: a systematic review and meta-analysis—Supplementary Materials

435 File format: PDF

436 Description: This supplementary materials contain: (i) details of search and data extraction  
437 strategies, (ii) detailed characteristics of the data sources, (iii) summary of risk of bias  
438 assessment, (iv) summary of additional analyses of study results, and (v) PRISMA checklists.

439

440 **List of abbreviations**

- 441 AGYW: adolescent girls and young women
- 442 (a)HR: (adjusted) hazard-ratio
- 443 AUC-ROC: area under the receiver operating characteristic curve
- 444 CHARMS: Critical Appraisal and Data Extraction for Systematic Reviews of Prediction
- 445 Modelling Studies Checklist
- 446 HSV-2: Human Simplex Virus – 2
- 447 MMC: male medical circumcision
- 448 PrEP: pre-exposure prophylaxis
- 449 PROBAST: Prediction Model Risk of Bias assessment tool checklist
- 450 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- 451 RCT: randomised controlled trial
- 452 STI: sexually transmitted infection
- 453

## 454 **References**

- 455 1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). End Inequalities. End  
456 AIDS. Global AIDS Strategy 2021-2026. 2021.
- 457 2. Global HIV Prevention Coalition. Implementation of the HIV Prevention 2020 Road Map.  
458 2020 [Available from: <https://www.unaids.org/en/resources/documents/2020>].
- 459 3. Global HIV Prevention Coalition. Implementation of the HIV Prevention 2020 Road Map  
460 First progress report, March 2018. 2018 [Available from:  
461 [https://www.unaids.org/en/resources/documents/2018/hiv-prevention-2020-road-map-](https://www.unaids.org/en/resources/documents/2018/hiv-prevention-2020-road-map-first-progress-report)  
462 [first-progress-report](https://www.unaids.org/en/resources/documents/2018/hiv-prevention-2020-road-map-first-progress-report)].
- 463 4. UNAIDS. 2021 UNAIDS Global AIDS Update — Confronting inequalities — Lessons for  
464 pandemic responses from 40 years of AIDS. 2021.
- 465 5. Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An Empiric HIV Risk  
466 Scoring Tool to Predict HIV-1 Acquisition in African Women. *Journal of Acquired Immune*  
467 *Deficiency Syndromes*. 2016;72(3):333-43.
- 468 6. Peebles K, Palanee-Phillips T, Balkus JE, Beesham I, Makkan H, Deese J, et al. Age-  
469 Specific Risk Scores Do Not Improve HIV-1 Prediction Among Women in South Africa.  
470 *Journal of acquired immune deficiency syndromes (1999)*. 2020;85(2):156-64.
- 471 7. Tanser F, Vandormael A, Cuadros D, Phillips AN, de Oliveira T, Tomita A, et al. Effect of  
472 population viral load on prospective HIV incidence in a hyperendemic rural African  
473 community. *Science translational medicine*. 2017;9(420):eaam8012.
- 474 8. Farahani M, Radin E, Saito S, Sachathep K, Hladik WA, Voetsch AC, et al. Population  
475 Viral Load, Viremia and Recent HIV-1 Infections: Findings from Population-based HIV  
476 Impact Assessments (PHIAs) in Zimbabwe, Malawi, and Zambia. *J Acquir Immune Defic*  
477 *Syndr*. 2021.
- 478 9. Anderson S-J, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising  
479 the effect of combination HIV prevention through prioritisation of the people and places  
480 in greatest need: a modelling study. *The Lancet*. 2014;384(9939):249-56.
- 481 10. UNAIDS. Prevailing against Pandemics: by Putting People at the Centre. 2020.
- 482 11. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al.  
483 Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling  
484 Studies: The CHARMS Checklist. *PLOS Medicine*. 2014;11(10):e1001744.

- 485 12. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al.  
486 PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies:  
487 Explanation and Elaboration. *Ann Intern Med*. 2019;170(1):W1-w33.
- 488 13. R Core Team. R: A language and environment for statistical computing. R Foundation  
489 for Statistical Computing, Vienna, Austria. 2020 [Available from: [https://www.R-](https://www.R-project.org/)  
490 [project.org/](https://www.R-project.org/)].
- 491 14. Balduzzi S, R cker G, Schwarzer G. How to perform a meta-analysis with R: a practical  
492 tutorial. *Evidence-Based Mental Health*. 2019:153-60.
- 493 15. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of*  
494 *Statistical Software*. 2010;3:1-48.
- 495 16. Zhou XH, Obuchowski N, McClish D. *Statistical Methods in Diagnostic Medicine*, Second  
496 Edition 2002.
- 497 17. MedCalc. Meta-analysis: area under ROC curve 2021 [Available from:  
498 <https://www.medcalc.org/manual/meta-analysis-ROC-area.php>].
- 499 18. Eaton J, Thomas M, Edun O, Howes A, Eilerts H, Jia K, et al. Risk scores for predicting  
500 HIV incidence among general population in sub-Saharan Africa: a systematic review.  
501 PROSPERO 2021 CRD42021236367 2021 [Available from:  
502 [https://www.crd.york.ac.uk/prospéro/display\\_record.php?ID=CRD42021236367](https://www.crd.york.ac.uk/prospéro/display_record.php?ID=CRD42021236367)].
- 503 19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The  
504 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*.  
505 2021;372:n71.
- 506 20. Wand H, Ramjee G. Assessing and evaluating the combined impact of behavioural and  
507 biological risk factors for HIV seroconversion in a cohort of South African women. *AIDS*  
508 *Care*. 2012;24(9):1155-62.
- 509 21. Wand H, Reddy T, Naidoo S, Moonsamy S, Siva S, Morar NS, et al. A Simple Risk  
510 Prediction Algorithm for HIV Transmission: Results from HIV Prevention Trials in  
511 KwaZulu Natal, South Africa (2002-2012). *AIDS & Behavior*. 2018;22(1):325-36.
- 512 22. Balkus JE, Brown ER, Palanee-Phillips T, Kiweewa FM, Mgodini N, Naidoo L, et al.  
513 Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African  
514 Women Participating in a Trial of the Dapivirine Vaginal Ring. *J AIDS*. 2018;77(1):E8-E10.

- 515 23. Burgess EK, Delany-Moretlwe S, Pisa P, Ahmed K, Sibiyi S, Gama C, et al. Validation  
516 of a risk score for HIV acquisition in young African women with facts 001. Topics in  
517 Antiviral Medicine. 2017;25 (1 Supplement 1):364s-5s.
- 518 24. Burgess EK, Yende-Zuma N, Castor D, Karim QA. An age-stratified risk score to predict  
519 HIV acquisition in young South African women. Topics in Antiviral Medicine. 2018;26  
520 (Supplement 1):419s.
- 521 25. Giovenco D, Pettifor A, MacPhail C, Kahn K, Wagner R, Piwowar-Manning E, et al.  
522 Assessing risk for HIV infection among adolescent girls in South Africa: an evaluation of  
523 the VOICE risk score (HPTN 068). Journal of the International AIDS Society.  
524 2019;22(7):e25359 - .
- 525 26. Rosenberg NE, Kudowa E, Price JT, Pettifor A, Bekker L-G, Hosseinipour MC, et al.  
526 Identifying Adolescent Girls and Young Women at High Risk for HIV Acquisition: A Risk  
527 Assessment Tool From the Girl Power-Malawi Study. Sexually Transmitted Diseases.  
528 2020;47(11):760-6.
- 529 27. Ayton SG, Pavlicova M, Abdool Karim Q. Identification of adolescent girls and young  
530 women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South  
531 Africa. Scientific reports. 2020;10(1):13017.
- 532 28. Kagaayi J, Gray RH, Whalen C, Fu P, Neuhauser D, McGrath JW, et al. Indices to  
533 measure risk of HIV acquisition in Rakai, Uganda. PLoS ONE. 2014;9(4).
- 534 29. Balzer LB, Havlir DV, Kanya MR, Chamie G, Charlebois ED, Clark TD, et al. Machine  
535 Learning to Identify Persons at High-Risk of Human Immunodeficiency Virus Acquisition  
536 in Rural Kenya and Uganda. Clinical Infectious Diseases. 2020;71(9):2326-33.
- 537 30. Roberts A, Cuadros D, Vandormael A, Gareta D, Barnabas R, Herbst K, et al. Predicting  
538 Risk of HIV Acquisition in Rural South Africa Using Geographic Data. Conference on  
539 Retroviruses and Opportunistic Infections (CROI) International Antiviral Society–USA  
540 2021.
- 541 31. Balkus J, Palnee-Phillips T, Zhang J, Kiweewa FM, Nair G, Pather A, et al. A validated  
542 risk score to predict HIV acquisition in African women: assessing risk score performance  
543 among women who participated in the aspire trial. AIDS research and human  
544 retroviruses. 2016;32:49 - .
- 545 32. Hosmer DWJ, Lemeshow S, Sturdivant RX. Applied Logistic Regression, Third Edition:  
546 John Wiley & Sons, Inc.; 2013.

- 547 33. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al.  
548 An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-Serodiscordant  
549 couples for targeted HIV-1 prevention. *Journal of Acquired Immune Deficiency*  
550 *Syndromes*. 2013;62(3):339-47.
- 551 34. Wahome E, Thiong'o AN, Mwashigadi G, Chirro O, Mohamed K, Gichuru E, et al. An  
552 Empiric Risk Score to Guide PrEP Targeting Among MSM in Coastal Kenya. *AIDS and*  
553 *Behavior*. 2018;22(1):35-44.
- 554 35. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A Risk  
555 Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit  
556 From Preexposure Prophylaxis. *Clin Infect Dis*. 2017;64(6):751-8.
- 557 36. Zemouri C, Wi TE, Kiarie J, Seuc A, Mogasale V, Latif A, et al. The Performance of the  
558 Vaginal Discharge Syndromic Management in Treating Vaginal and Cervical Infection: A  
559 Systematic Review and Meta-Analysis. *PLOS ONE*. 2016;11(10):e0163365.
- 560 37. Barry MS, Ba Diallo A, Diadhiou M, Mall I, Gassama O, Ndiaye Guèye MD, et al.  
561 Accuracy of syndromic management in targeting vaginal and cervical infections among  
562 symptomatic women of reproductive age attending primary care clinics in Dakar,  
563 Senegal. *Tropical Medicine & International Health*. 2018;23(5):541-8.
- 564 38. Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, et al. Diagnosing  
565 sexually transmitted infections in resource-constrained settings: challenges and ways  
566 forward. *Journal of the International AIDS Society*. 2019;22(S6):e25343.
- 567 39. Balkus JE, Brown ER, Palanee-Phillips T, Matovu Kiweewa F, Mgodhi N, Naidoo L, et al.  
568 Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African  
569 Women Participating in a Trial of the Dapivirine Vaginal Ring. *Journal of acquired*  
570 *immune deficiency syndromes (1999)*. 2018;77(1):e8-e10.
- 571 40. Marcus JL, Sewell WC, Balzer LB, Krakower DS. Artificial Intelligence and Machine  
572 Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic. *Current*  
573 *HIV/AIDS Reports*. 2020;17(3):171-9.

**Table 1. Characteristics of the cohorts from which HIV risk scores were developed and/or validated**

| First author (Year)     | Cohort (Study design)           | Dev/Val <sup>§</sup> | Year of study | Sites   | Study population   | Sex | Age <sup>†</sup>         | Settings  | N (Total PYs) | Incidence (per 100 PYs) |
|-------------------------|---------------------------------|----------------------|---------------|---|--|-----|--------------------------|---|---------------|-------------------------|
| <b>Wand (2012)</b>      | MIRA (RCT)                      | Dev**                | 2003-2006     | Durban, KwaZulu-Natal, South Africa (2 sites) | 18-49 yrs old, sexually active, non-pregnant, willing to use contraception       | F   | Mean: 27<br>IQR: 22-34   | Family-planning clinics and other community-based organisation  | 1485‡ (2162)  | 6.85                    |
| <b>Wand (2018)</b>      | Multiple <sup>¶</sup> (RCT)     | Dev**                | 2002-2012     | KwaZulu-Natal, South Africa (multiple sites)  | 16+ yrs old, sexually active, non-pregnant, willing to use contraception         | F   | Median: 27<br>IQR: 22-33 | Various clinical study sites  | 8982‡ (11038) | 7.03                    |
| <b>Balkus (2016)</b>    | VOICE (RCT)                     | Dev*                 | 2009-2011     | South Africa, Uganda, and Zimbabwe            | 18-45 yrs old, sexually active, non-pregnant, willing to use contraception       | F   | Median: 24<br>IQR: 21-29 | STD clinics, family planning clinics, and post-natal clinics, community-based locations   | 4834 (4348)   | 6.05                    |
|                         | HPTN 035 (RCT)                  | Val                  | 2005-2009     | Malawi, South Africa, Zimbabwe, and Zambia    | 18+ yrs old, sexually active, not (intended to be) pregnant.                     | F   | 25 (22-29)               | STD clinics, family planning clinics, and post-natal clinics, community-based locations   | 2848 (2903)   | 3.38                    |
|                         | FEM-PrEP (RCT)                  | Val                  | 2009-2011     | Kenya, South Africa, and Tanzania             | sexually active, non-pregnant, 18-35 yrs old women at high risk                  | F   | 23 (20-27)               | Community outreach, recruitment sites, community partners, health centres, STI clinics, HIV voluntary testing and counselling centres | 1804 (1231)   | 4.79                    |
| <b>Balkus (2018)</b>    | ASPIRE (RCT)                    | Val                  | 2012-2015     | Malawi, South Africa, Uganda, and Zimbabwe    | 18-45 yrs old, sexually active, not (intended to be) pregnant                    | F   | <25 (39%)                | STIs, family-planning clinics   | 2539 (2566)   | 3.70                    |
| <b>Burgess (2018)</b>   | CAPRISA 004 (RCT)               | Dev                  | 2007-2010     | KwaZulu-Natal, South Africa (2 sites)         | 18-40 yrs old, sexually active women, non-pregnant, willing to use contraception | F   | <25 (68%)                | An urban and a rural CAPRISA research clinic  | 431 (660.7)   | 9.08                    |
| <b>Burgess (2017)</b>   | FACTS 001 (RCT)                 | Val                  | 2011-2014     | South Africa (9 sites)                        | 18-30 yrs old, sexually active, non-pregnant, willing to use contraception       | F   | Median: 23<br>IQR: 20-25 | 9 community-based clinical trial sites  | 1115 (1876)   | 4.32                    |
| <b>Peebles (2020)</b>   | ECHO (RCT)                      | Dev*                 | 2015-2018     | South Africa (9 sites)                        | 18-35 yrs old, sexually active, seeking effective contraception                  | F   | <25 (62.1%)              | 9 clinics over 5 provinces  | 5670 (5573)   | 5.4 (<25)<br>3.4 (25+)  |
| <b>Giovenco (2019)</b>  | HPTN 068 (RCT)                  | Val                  | 2011-2012     | South Africa (single site)                    | school-attending 13-20 yrs old AGYW  | F   | Median: 15<br>IQR: 14-17 | a random sample in the rural Bushbuckridge in Mpumalanga province   | 2178 (2455)   | 1.34                    |
| <b>Rosenberg (2020)</b> | Girl Power (Quasi-experimental) | Dev*                 | 2016-2017     | Malawi (4 sites)                              | sexually active, 15-24 yrs old AGYW  | F   | <20 (58.7%)              | 4 public-sector health centers in Lilongwe, Malawi  | 795 (672)     | 2.08                    |
| <b>Ayton (2020)</b>     | CAPRISA 007 (RCT)               | Val                  | 2010-2012     | South Africa (14 sites)                       | 14-25 yrs old school-attending AGYW  | F   | Median: 17<br>IQR: 16-18 | Grade 9 and 10 students in 14 schools in Vulindlela   | 971 (-)       | 1.72                    |

|                       |                |       |           |   |                                |     |                       |  |                |                                  |
|-----------------------|----------------|-------|-----------|---|--------------------------------|-----|-----------------------|--|----------------|----------------------------------|
| <b>Kagaayi (2014)</b> | RCCS (Cohort)  | Dev*  | 2003-2011 | Uganda (~50 communities)  | sexually active, 15–49 yrs old | F   | Mean: 27.0<br>SD: 7.8 | Communities in Rakai district            | 7497           | 1.11                             |
|                       |                |       |           |   |                                | M   | Mean: 28.3<br>SD: 8.0 |  | 5783           | 0.98                             |
| <b>Balzer (2020)</b>  | SEARCH (RCT)   | Dev*  | 2018      | Kenya and Uganda (16 communities)                                 | 15+ years old residents        | F M | <25 (39%)             | 16 communities in rural Uganda and Kenya | 75558 (-)      | 0.27-0.37                        |
| <b>Roberts (2021)</b> | ACDIS (Cohort) | Dev** | 2012-2019 | Umkanyakude district of KwaZulu-Natal, South Africa (single site) | 15+ years old residents        | F   | -                     | A community in Mtubatuba town            | 11933‡ (28422) | 4.20 (2012-15)<br>3.11 (2016-19) |
|                       |                |       |           |   |                                | M   | -                     |  | 7623‡ (16449)  | 1.80 (2012-15)<br>1.16 (2016-19) |

§ Dev: model development (marked with \* if the authors did re-sampling procedures through cross-validation or bootstrapping to obtain the AUC-ROC for internal validation of their score(s), and \*\* if they split the sample into training and testing sets as part of their internal validation); Val: external validation of the risk score in a study population different from which the score was originally developed. Peebles [6], Burgess (2018) [24] and Rosenberg [26] developed their own risk scores while also using their samples to externally validate the VOICE score developed by Balkus [5]; AUC-ROCs are provided in Table 3.

¶ Multiple cohort studies included: MIRA, MDP 301, NCT00213083, VOICE, HPTN035. † Mean/median (IQR)

‡ Total sample size is provided here, whereas the authors split the sample into training and testing sets.

**Table 2. Risk factors retained in the final models and their adjusted effects**

|                           | Women only, all ages (RCTs) <sup>†</sup> |             |             |               |                  | AGYW only (RCT / quasi-experimental trials) <sup>††</sup> |                  |                         |                  | General population <sup>#</sup> |                |       |
|---------------------------|--|-------------|-------------|---------------|------------------|---|------------------|-------------------------|------------------|---------------------------------|----------------|-------|
|                           | Retainment ratio                         | Wand (2012) | Wand (2018) | Balkus (2016) | Peebles (2020)   | Retainment ratio  | Peebles (2020)   | Burgess (2018)          | Rosenberg (2020) | Kagaayi (2014)                  | Kagaayi (2014) |       |
| Cohort                    |  | MIRA        | Multiple    | VOICE         | ECHO 25+ yrs old |   | ECHO <25 yrs old | CAPRISA 004 <25 yrs old | GirlsPower       | RCCS female                     | RCCS male      |       |
| <b>Demographic</b>        | Age (younger)                            | 3/4         | N.I.        | 1.75-2.93***  | 1.70*            | 2.12*   | 0/3              |                         | N.I.             | 1.03*                           | 0.81*          |       |
|                           | Age of sexual debut (<16)                | 1/1         |             | 1.38*         |                  |   |                  |                         |                  |                                 |                |       |
|                           | Not married/living with partners         | 4/4         | 2.63**      | 3.62***       | 1.80*            | 1.85*   | 0/3              | N.I.                    | N.I.             | N.I.                            | 1.72-2.08*     | N.I.  |
|                           | Pregnancy history                        |             |             |               |                  |   | 1/2              | N.I.                    |                  | 4.55*                           |                |       |
|                           | Parity (less)                            | 1/3         |             | 2.62***       | N.I.             | N.I.  | 0/1              | N.I.                    |                  |                                 |                |       |
|                           | Education (Higher)                       | 0/4         | N.I.        | N.I.          | N.I.             | N.I.  | 0/2              | N.I.                    |                  | N.I.                            | 0.83^          | 0.56* |
|                           | High-risk occupation*                    |             |             |               |                  |   |                  |                         |                  |                                 | 1.32*          |       |
|                           | Perceived HIV risk (High)                |             |             |               |                  |   |                  |                         |                  |                                 | 1.49*          |       |
|                           | Alcohol use                              | 1/3         | N.I.        |               | 1.41*            | N.I.  | 1/2              | 1.45*                   |                  | N.I.                            |                |       |
|                           | Partner >5 y older                       |             |             |               |                  |   | 1/1              |                         |                  | 2.42^                           |                |       |
| <b>Partnership factor</b> | Partner in high risk occupation          |             |             |               |                  |   |                  |                         |                  |                                 | 1.89*          |       |
|                           | Fin. support from partner                | 1/3         | N.I.        |               | 0.72*            | N.I.  | 0/3              | N.I.                    | N.I.             | N.I. <sup>#</sup>               |                |       |
|                           | Partner has other partners:              |             |             |               |                  |   |                  |                         |                  |                                 |                |       |
|                           | Don't know vs No                         | 1/2         |             |               | 1.81*            | N.I.  | 1/1              |                         | 7.56*            |                                 |                |       |
|                           | Yes vs No                                | 1/3         | N.I.        |               | 1.63*            | N.I.  | 2/3              |                         | 7.86*            | N.I.                            |                |       |
|                           | Yes/don't know vs No                     |             |             |               |                  |   |                  | 1.31^                   |                  |                                 |                |       |
|                           | Partner has unknown HIV status           |             |             |               |                  |   |                  |                         |                  |                                 |                | 1.82* |
|                           | No. of partners <sup>†</sup>             | 2/4         |             |               | N.I.             | N.I.  | 2/3              | 1.61*                   | 2.19*            | N.I.                            | 1              | 1     |
|                           | 2 (ref : 1)                              |             | 1.34^       |               |                  |   |                  |                         |                  |                                 | 1.59*          | 1.21* |
|                           | 3 (ref : 1)                              |             | 1.93*       |               |                  |   |                  |                         |                  |                                 |                | 1.90* |
| 3+ (ref: <2)              |  |             | 1.61***     |               |                  |   |                  |                         |                  |                                 |                |       |
| New sex partner           |  |             |             |               |                  |   |                  |                         |                  | 1.45*                           |                |       |
| Concurrent relationships  |  |             |             |               |                  |   |                  |                         |                  | 1.50^                           |                |       |

|                                      |                                     |     |                    |                     |                   |                   |                   |  |                   |                   |                   |                   |
|--------------------------------------|-------------------------------------|-----|--------------------|---------------------|-------------------|-------------------|-------------------|--|-------------------|-------------------|-------------------|-------------------|
| Transmission probability             | Condom use (Yes)                    | 1/3 | N.I.               | N.I.                | N.I.              | 1/1               | 1.34 <sup>^</sup> |  |                   |                   |                   |                   |
|                                      | Oral contraceptive (Yes)            | 0/1 |                    | N.I.                |                   |                   |                   |  |                   |                   |                   |                   |
|                                      | Inject. Contraceptive (Yes)         | 1/1 |                    | 1.43 <sup>***</sup> |                   |                   |                   |  |                   |                   |                   |                   |
|                                      | High risk sex                       | 1/1 | 1.96 <sup>*</sup>  | -                   |                   |                   |                   |  |                   | 1.44 <sup>*</sup> | 1.28 <sup>*</sup> |                   |
|                                      | MMC of primary partners/ MMC (male) | 0/3 |                    | N.I.                | N.I.              | N.I.              | 0/2               | N.I.                                     | N.I.              |                   | 0.61 <sup>*</sup> |                   |
|                                      | HSV-2 <sup>§</sup>                  | 2/4 |                    |                     | 1.63 <sup>*</sup> | 1.88 <sup>*</sup> | 3/3               | 1.51 <sup>*</sup>                        | 2.54 <sup>*</sup> | 1.94 <sup>^</sup> |                   |                   |
| STIs/ genital infection <sup>‡</sup> | 4/4                                 |     | 1.60 <sup>**</sup> | 1.57 <sup>***</sup> | 1.49 <sup>*</sup> | 2.22 <sup>*</sup> | 2/3               | 2.07 <sup>*</sup>                        | N.I.              | 2.61 <sup>^</sup> | 1.75 <sup>*</sup> | 1.78 <sup>*</sup> |
| Community                            | Community type                      |     |                    |                     |                   |                   |                   |  |                   |                   |                   | 1.67 <sup>*</sup> |
|                                      | Community prevalence                | 0/1 |                    |                     |                   | N.I.              | 1/1               | 1.64 <sup>*</sup> -<br>1.81 <sup>*</sup> |                   |                   | 1.03 <sup>*</sup> | 1.03 <sup>*</sup> |
|                                      | Province                            | 1/1 |                    |                     |                   | 9.05 <sup>*</sup> |                   |  |                   |                   |                   |                   |
| Adjusted for sites (Y/N)             |                                     |     | N                  | N                   | Y                 | Y                 |                   | Y  |                   |                   | Y                 | Y                 |
| AUC-ROC                              |                                     |     | 0.79 <sup>§§</sup> | 0.71 <sup>§§</sup>  | 0.69 <sup>§</sup> | 0.64 <sup>§</sup> |                   | 0.62 <sup>§</sup>                        | 0.7               | 0.79              | 0.67 <sup>§</sup> | 0.69 <sup>§</sup> |
| 95% CI                               |                                     |     | 0.70-0.81          | -                   | 0.66-0.72         | 0.59-0.69         |                   | 0.58-0.64                                | 0.60-0.79         | 0.69-0.89         | 0.64-0.70         | 0.66-0.73         |

<sup>^</sup> Women recruited from RCTs were sexually active and willing to use effective contraception during the study period

# Balzer [29] and Roberts [30] also developed risk scores in their studies, but the final models were not available and thus details are not shown in Table. Risk factors considered by these analyses are reported in Table S2.

\* Detailed list of high-risk occupations is provided by Kagaayi (2014) [28].

'N.I.' indicates risk factor was measured but not selected for inclusion in final model; Dark grey shaded cells indicate risk factor was not considered as a candidate predictor in the study; Light grey shaded cells in the *Retention Ratio* column indicates risk factor not considered by any models.

\* (p<0.05); \*\* (p<0.01); \*\*\* (p<0.0001) significant and included in the final risk score;

<sup>^</sup> (p>0.05) not significant but included

<sup>†</sup> Wand (2012) [20] considered lifetime number of sex partners, while all others considered recent number of sex partners( Table S1 contains details on temporality of sexual partners for each study).Casual partnerships (none vs at least one) among sexually-active women was considered as a proxy for multiple partners in Burgess (2018) [24] study.

<sup>‡</sup> Methods for STIs status assessment varied by studies; details are provided in Table S2 of the Supplementary Materials.

# Although partners' financial support from were not included in the final model, all HIV cases (n=14) in Rosenberg [26] engaged in transactional sex.

<sup>§</sup> AUC-ROC was obtained through cross-validation or bootstrapping of the original derivation set for the internal validation; <sup>§§</sup> AUC-ROC was based on a "testing" set different from the "training" set for which the score was derived.

**Table 3. Predictive performance measures**

| First author (Year) | Dev <sup>¶</sup> | Cohort (Study design)           | HIV incident cases    | Prediction horizon | Score developed               | AUC-ROC (95% CI)     | Val <sup>¶</sup> | Predictors available | Score externally validated | AUC-ROC (95% CI)                       |
|---------------------|------------------|---------------------------------|-----------------------|--------------------|-------------------------------|----------------------|------------------|----------------------|----------------------------|--|
| Wand (2012)         | 1 **             | MIRA (RCT)                      | 148                   | 1 to 2 yrs         | Wand-2012                     | 0.79 (0.70, 0.81) ** | -                | -                    | -                          | -                                      |
| Wand (2018)         | 1 **             | Multiple § (RCT)                | 776                   | 1 to 2+ yrs        | Wand-2018                     | 0.71 (-)**           | 1                | -                    | -                          | -                                      |
| Balkus (2016)       | 1*               | VOICE (RCT)                     | 263                   | 1 yr               | VOICE                         | 0.69 (0.66, 0.72) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | VOICE (Modified)              | 0.67 (0.64, 0.70) *  | 1                | -                    | -                          | -                                      |
|                     |                  | HPTN 035 (RCT)                  | 98                    | 1 yr               |                               |                      | -                | 6/7                  | VOICE                      | 0.70 (0.65, 0.75)                      |
|                     |                  | FEM-PrEP (RCT)                  | 59                    | 1 yr               |                               |                      | -                | 6/7                  | VOICE                      | 0.63 (-)                               |
|                     |                  |                                 |                       |                    |                               |                      | -                | 4/5                  | VOICE (Modified)           | 0.58 (0.51, 0.65)                      |
| Balkus (2018)       | -                | ASPIRE (RCT)                    | 95                    | 1 yr               |                               |                      | 1                | 5/7                  | VOICE                      | 0.69 (0.64, 0.74)                      |
| Burgess (2018)      | 1                | CAPRISA 004 (RCT)               | 47 (<25)<br>13 (25+)  | 18 mo              | Burgess (under 25)            | 0.70 (0.60, 0.79)    | 1                | All <sup>#</sup>     | VOICE                      | 0.66 (0.54, 0.74)                      |
|                     |                  |                                 |                       |                    | Burgess (under 25) (Modified) | 0.62 (0.56, 0.68)    |                  |                      | VOICE (under 25)           | 0.69 (0.60, 0.78)                      |
| Burgess (2017)      | -                | FACTS 001 (RCT)                 | 81                    | 2.2 yrs            |                               |                      | 1                | All <sup>#</sup>     | VOICE                      | 0.49 (0.30, 0.63)<br>0.56 (0.50, 0.62) |
| Peebles (2020)      | 2 *              | ECHO (RCT)                      | 188 (<25)<br>72 (25+) | 1 yr               |                               |                      | 1                | All                  | VOICE                      | 0.61 (0.58, 0.65)                      |
|                     |                  |                                 |                       |                    |                               |                      |                  |                      | VOICE (Modified)           | 0.59 (0.56, 0.62)                      |
|                     |                  |                                 |                       |                    | Peebles (under-25)            | 0.62 (0.58, 0.64) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | Peebles (under-25) (Modified) | 0.59 (0.55, 0.61) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | Peebles (25+)                 | 0.64 (0.59, 0.69) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | Peebles (25+) (Modified)      | 0.62 (0.58, 0.67) *  | -                | -                    | -                          | -                                      |
| Giovenco (2019)     | -                | HPTN 068 (RCT)                  | 33                    | 1 yr               |                               |                      | 1                | 6/7                  | VOICE                      | 0.55 (0.44, 0.65)                      |
| Rosenberg (2020)    | 1 *              | Girl Power (Quasi-experimental) | 14                    | 1 yr               | Rosenberg                     | 0.79 (0.69, 0.89) *  | 1                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    |                               |                      | -                | All <sup>#</sup>     | VOICE                      | 0.64 (0.52, 0.75)                      |
| Ayton (2020)        | -                | CAPRISA 007 (RCT)               | 18                    | 1 yr               |                               |                      | 1                | 4/7                  | VOICE                      | -                                      |
| Kagaayi (2014)      | 2 *              | RCCS (Cohort)                   | 342                   | 1 yr               | Kagaayi (female)              | 0.67 (0.64, 0.70) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | Kagaayi (male)                | 0.69 (0.66, 0.73) *  | -                | -                    | -                          | -                                      |
| Balzer (2020)       | 3 *              | SEARCH (RCT)                    | 519                   | 1 yr               | Balzer (Risk group-based)     | 0.59 (0.55, 0.62) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | Balzer (Model-based)          | 0.70 (0.68, 0.73) *  | -                | -                    | -                          | -                                      |
|                     |                  |                                 |                       |                    | Balzer (Machine-learning)     | 0.73 (0.71, 0.76) *  | -                | -                    | -                          | -                                      |


|                       |      |                |      |      |   |         |   |   |   |   |
|-----------------------|------|----------------|------|------|---|---------|---|---|---|---|
| <b>Roberts (2021)</b> | 2 ** | ACDIS (Cohort) | 1160 | 1 yr | Roberts (female)                                    | 0.68 ** | - | - | - | - |
|                       |      |                |      |      | Roberts (female) (age + geographic covariates only) | 0.65 ** |   |   |   |   |
|                       |      |                | 248  | 1 yr | Roberts (male)                                      | 0.72 ** | - | - | - | - |
|                       |      |                |      |      | Roberts (male) (age + geographic covariates only)   | 0.71 ** |   |   |   |   |

<sup>†</sup>Number of risk score(s) developed (“Dev”) / externally validated (“Val”) by the study


\* AUC-ROC was obtained through cross-validation or bootstrapping of the original derivation set for the internal validation; \*\* AUC-ROC was based on a “testing” set different from the “training” set for which the score was derived. Wand (2012) [20] and Wand (2018) [21] did a random split of data sets, while Roberts [30] split the data by time periods (2012-2015 vs 2016-2019).

# Self-reported STIs histories or symptoms were used as proxies for curable STIs and HSV-2 status in Burgess (2017) [23] and Rosenberg [26], and for curable STIs in Burgess (2018) [24].


## Figures




**Figure 1.** Study selection.




**Figure 2.** Forest plots of risk factor estimates among women in general. Adjusted (A) and unadjusted (B) effects were pooled together for: (i) marital / cohabiting status, (ii) age, (iii) number of sexual partners, (iv) partners having other partners, (v) curable sexually transmitted infection (STIs) and (vi) HSV-2.



**Figure 3.** Forest plots of risk factor estimates among adolescent girls and young women (AGYW). Adjusted (A) and unadjusted (B) effects were pooled together for (i) marital / cohabiting status (ii) number of sexual partners, (iii) partners having other partners, (iv) curable sexually transmitted infection (STIs) and (v) HSV-2.



**Figure 4.** Forest plot (A) and funnel plot (B) for the area-under-curve of the receiver operating characteristic curves (AUC-ROCs) from external validation studies for the VOICE score. Studies with <sup>^</sup> did not collect all the predictors intended by the model (Details are in Table 3). Those with \* used self-reported STIs history, syndromic management or self-reported symptoms in place of laboratory diagnosed STIs status at baseline as intended by the original VOICE score (Details are in Table 3 and Table S2).



**Figure 5.** Percentage of individuals identified as high risk among incident cases versus proportion classified as high risk for: (i) women enrolled in clinical trials (A), (ii) AGYW (B), and (iii) the general population (C). When the highest score was used as the threshold, few or none were classified as high risk and they took up a small fraction of all HIV incident cases (indicated by the origin). When the lowest score was used, all were classified as high risk and all incident cases were among them. Dev: Development set; Val: Validation set.